Insider Buying: DENTSPLY SIRONA (NASDAQ:XRAY) Director Acquires $100,049.70 in Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Brian Gladden bought 9,985 shares of DENTSPLY SIRONA stock in a transaction dated Monday, June 15th. The stock was purchased at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the purchase, the director directly owned 61,849 shares in the company, valued at $619,726.98. This represents a 19.25% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

DENTSPLY SIRONA Stock Down 4.0%

Shares of NASDAQ:XRAY opened at $10.03 on Thursday. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $17.09. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53. The company’s fifty day moving average is $10.90 and its 200-day moving average is $11.69. The company has a market capitalization of $2.01 billion, a PE ratio of -3.18, a P/E/G ratio of 1.24 and a beta of 0.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. During the same quarter in the prior year, the firm posted $0.43 EPS. The firm’s revenue for the quarter was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities research analysts predict that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current fiscal year.

Institutional Trading of DENTSPLY SIRONA

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Eagle Investment Management LLC grew its position in shares of DENTSPLY SIRONA by 3.2% in the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock valued at $167,342,000 after purchasing an additional 458,744 shares during the period. Sound Income Strategies LLC grew its position in shares of DENTSPLY SIRONA by 32.3% in the 4th quarter. Sound Income Strategies LLC now owns 611,308 shares of the medical instruments supplier’s stock valued at $7,464,000 after purchasing an additional 149,384 shares during the period. Skba Capital Management LLC grew its position in shares of DENTSPLY SIRONA by 14.3% in the 3rd quarter. Skba Capital Management LLC now owns 1,140,430 shares of the medical instruments supplier’s stock valued at $14,472,000 after purchasing an additional 142,900 shares during the period. Invenomic Capital Management LP boosted its position in DENTSPLY SIRONA by 48.7% during the 3rd quarter. Invenomic Capital Management LP now owns 4,351,199 shares of the medical instruments supplier’s stock worth $55,217,000 after acquiring an additional 1,425,637 shares during the last quarter. Finally, Crawford Investment Counsel Inc. bought a new position in shares of DENTSPLY SIRONA during the 3rd quarter worth approximately $1,104,000. 95.70% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on XRAY. Barclays reduced their target price on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research note on Thursday, June 4th. Weiss Ratings cut DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Robert W. Baird lifted their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Barrington Research lifted their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Finally, Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and lifted their price target for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Three analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $13.55.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.